Tuberculosis (TB) drug resistance, particularly multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB), is a major global health challenge. It occurs when Mycobacterium tuberculosis no longer responds to first-line drugs like isoniazid and rifampicin, making treatment longer, costlier, and less effective. Drug-resistant TB increases morbidity and mortality, complicates public health efforts, and poses a serious threat to global infectious disease control. Early detection through molecular diagnostics, adherence to treatment, and development of novel therapeutics are critical in addressing this crisis.
Market Analysis: In 2025, the global tuberculosis drug resistance market—including diagnostics, second-line therapies, and novel drug development—is valued at about USD 3.2 billion. With growing investments in rapid molecular testing, shorter treatment regimens, and global health initiatives, the market is projected to reach USD 5.6 billion by 2030, at a CAGR of 11.1%. High-burden regions such as Asia and Africa dominate demand due to elevated TB prevalence, while North America and Europe lead in R&D and funding for innovative treatment solutions. Expansion of public-private partnerships and WHO-backed initiatives will further drive market growth.
